X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the terms of agreement, Lonza will provide kilogram-scale synthesis, purification, and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply. Oasmia will leverage Lonza’s extensive experience in manufacturing highly-potent API.
Lead Product(s): Cantrixil
Therapeutic Area: Oncology Product Name: TRX-E-002-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lonza Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 21, 2022
Details:
Oasmia will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer.
Lead Product(s): Cantrixil
Therapeutic Area: Oncology Product Name: TRE-E-002-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oasmia Pharmaceutical
Deal Size: $46.0 million Upfront Cash: $4.0 million
Deal Type: Licensing Agreement March 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
